1-12 of 12
Betty Y Chang, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Hsu-Ping Kuo, PhD, Sidney Hsieh, MSc, Jennifer Whang, PhD, Yujun Huang, PhD, Mint Sirisawad, BS, Betty Y. Chang, PhD
Journal: Blood
Blood (2016) 128 (22): 4140.
https://doi.org/10.1182/blood.V128.22.4140.4140
Published: 2016
Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD
Journal: Blood
Blood (2015) 126 (23): 3998.
https://doi.org/10.1182/blood.V126.23.3998.3998
Published: 2015
Journal Articles

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Sidney Hsieh, Karl J. Schweighofer, Leo WK Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Betty Y. Chang, PhD
Journal: Blood
Blood (2015) 126 (23): 699.
https://doi.org/10.1182/blood.V126.23.699.699
Published: 2015
Journal Articles

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Stephan Stilgenbauer, MD, Jeffrey A. Jones, MD MPH, Steven Coutre, MD, Anthony R. Mato, MD MSCE, Peter Hillmen, MB, ChB, PhD, Constantine Tam, MBBS, MD, Anders Osterborg, MD PhD, Tanya Siddiqi, MD, Michael J. Thirman, MD, Richard R. Furman, MD, Osman Ilhan, Michael Keating, MBBS, Timothy G. Call, MD, Jennifer R. Brown, MD PhD, Yunfeng Li, PhD, Karl Eckert, BA, Betty Y. Chang, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, Michael Hallek, MD, Susan O'Brien, MD
Journal: Blood
Blood (2015) 126 (23): 833.
https://doi.org/10.1182/blood.V126.23.833.833
Published: 2015
Journal Articles

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Richard R. Furman, MD, Shuhua Cheng, PhD, Pin Lu, MD, PhD, Menu Setty, Alexandar Perez, Ailin Guo, MD, PhD, Joelle Racchumi, BS, Jiao Ma, PhD, Morton Coleman, MD, Kabaleeswaran Venkataraman, PhD, Guozhou Xu, PhD, Wei Chen, PhD, Hao Wu, PhD, Betty Y. Chang, PhD, Christina Leslie, PhD, Y. Lynn Wang, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4914.
https://doi.org/10.1182/blood.V122.21.4914.4914
Published: 2013
Journal Articles

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Carsten U Niemann, MD, PhD, Angelique Biancotto, PhD, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, J. Philip McCoy, Jr., Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2856.
https://doi.org/10.1182/blood.V122.21.2856.2856
Published: 2013
Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD
Journal: Blood
Blood (2012) 120 (21): 183.
https://doi.org/10.1182/blood.V120.21.183.183
Published: 2012
Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jason A Dubovsky, Ph.D, Kyle A Beckwith, B.S., Jennifer A. Woyach, MD, Samantha M. Jaglowski, MD, MPH, Joshua Hessler, Betty Y. Chang, PhD, Karilyn Larkin, Matthew R Stefanovski, B.S., Frank W Frissora, M.S., Lisa L. Smith, Kelly A Smucker, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Leslie A Andritsos, MD, Kami Maddocks, MD, Amy Lehman, Richard R. Furman, MD, Jeff Sharman, MD, Anjali Mishra, Ph.D., Michael A. Caligiuri, M.D., Joseph J. Buggy, PhD, Natarajan Muthusamy, DVM, Ph.D, Amy J Johnson, PhD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 775.
https://doi.org/10.1182/blood.V120.21.775.775
Published: 2012
Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2012) 120 (21): 4039.
https://doi.org/10.1182/blood.V120.21.4039.4039
Published: 2012
Journal Articles

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Yu-Tzu Tai, PhD, Betty Y Chang, PhD, Sun-Young Kong, MD, PhD, Mariateresa Fulciniti, PhD, Guang Yang, PhD, Yolanda Calle, PhD, Yiguo Hu, MD, PhD, Jianhong Lin, PhD, Jian-Jun Zhao, PhD, Michele Cea, MD, Antonia Cagnetta, MD, Michael A Sellitto, BS, Michelle Chen, Zachary Hunter, BS, Ruben Carrasco, MD, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD, William Matsui, MD, Steven P Treon, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2011) 118 (21): 883.
https://doi.org/10.1182/blood.V118.21.883.883
Published: 2011
Journal Articles

Btk Inhibitor, PCI-32765, Delays CLL Progression in a TCL1 Adoptive Transfer Model by Impairing Migration and Cell Proliferation

Shih-Shih Chen, Ph.D., Joseph J. Buggy, PhD, Betty Y Chang, PhD, Jan A. Burger, MD, PhD, Nicholas Chiorazzi, M.D.
Journal: Blood
Blood (2011) 118 (21): 982.
https://doi.org/10.1182/blood.V118.21.982.982
Published: 2011
Journal Articles

Egress of CD19 + CD5 + Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients

Betty Y Chang, PhD, Michelle Francesco, Padmaja Magadala, Min Mei Huang, PhD, Marcel Spaargaren, PhD, Joseph J. Buggy, PhD, Laurence Elias, MD
Journal: Blood
Blood (2011) 118 (21): 954.
https://doi.org/10.1182/blood.V118.21.954.954
Published: 2011